Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK6 | Q00534 | 16/20 | 0.88 |
| ▸ | CDK4 | P11802 | 15/20 | 0.88 |
| ▸ | CDK1 | P06493 | 12/20 | 0.88 |
| ▸ | CCND3 | P30281 | 8/20 | 0.88 |
| ▸ | CCND1 | P24385 | 5/20 | 0.88 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.88 |
| ▸ | CDK2 | P24941 | 3/20 | 0.88 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.88 |
| ▸ | DYRK2 | Q92630 | 2/20 | 0.88 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.88 |
| ▸ | CIT | O14578 | 1/20 | 0.88 |
| ▸ | GAK | O14976 | 1/20 | 0.88 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.88 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.88 |
| ▸ | STK16 | O75716 | 1/20 | 0.88 |
| ▸ | CCNK | O75909 | 1/20 | 0.88 |
| ▸ | STK10 | O94804 | 1/20 | 0.88 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.88 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.88 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15252367 | 0.96 | CDK6 (0.89) | CDK6CDK4CDK1CCND3CCND1 | |
| SCHEMBL19220702 | 0.94 | CDK6 (0.79) | CDK6CDK4CDK1CCND3CCND1 | |
| Abemaciclib SCHEMBL29356350 | 0.94 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CCND1 | |
| Abemaciclib SCHEMBL2487229 | 0.94 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CCND1 | |
| SCHEMBL15252470 | 0.94 | CDK6 (0.88) | CDK6CDK4CDK1CCND3CCND1 | |
| Abemaciclib SCHEMBL29423472 | 0.94 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CCND1 | |
| Abemaciclib SCHEMBL29591527 | 0.94 | CDK4 (1.00) | CDK6CDK4CDK1CCND3CCND1 | |
| SCHEMBL17488760 | 0.94 | CDK4 (0.88) | CDK6CDK4CDK1CCND3CCND1 | |
| SCHEMBL17489114 | 0.93 | CDK4 (0.87) | CDK6CDK4CDK1CCND3CCND1 | |
| SCHEMBL21658739 | 0.93 | CDK4 (0.87) | CDK6CDK4CDK1CCND3CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023192578-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | ENDOTARGET INC. | 2023-09-21 | — | — | US | disclosed |
| US-20220143183-A1 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | NEW YORK UNIVERSITY | 2022-05-12 | — | — | US | disclosed |
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | ACERTA PHARMA BV (NL) | 2017-08-10 | — | — | US | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2379528-B1 | PROTEIN KINASE INHIBITORS | LILLY CO ELI (US) | 2013-09-18 | — | — | EP | disclosed |
| EP-2379528-A1 | PROTEIN KINASE INHIBITORS | Eli Lilly and Company (US) | 2011-10-26 | — | — | EP | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| US-7855211-B2 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY (US) | 2010-12-21 | — | — | US | disclosed |
| WO-2010075074-A1 | PROTEIN KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160340-A1 | such as [5-(4-Ethyl-piperazin-1-ylmethyl)-pyridin-2-yl]-[5-fluoro-4-(7-fluoro-3-isopropyl-2-methyl-3H-benzoimidazol-5-yl)-pyrimidin-2-yl]-amine, useful in the treatment of cell proliferative diseases | MKI67, PKD1, CCNI | CDK6 86/4885CDK4 26/4885CDK1 155/4885 |
| US-20230295118-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | CDK6, CDK4, CDK1 | CDK6 1/4885CDK4 2/4885CDK1 3/4885 |
| US-20220143183-A1 | PHOTOSWITCHABLE PROTACS AND SYNTHESIS AND USES THEREOF | MDM2, UBE3C, CUL1 | CDK6 541/4885CDK4 234/4885CDK1 355/4885 |
| US-20170224819-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor | BTK, CDK6, CDK4 | CDK6 2/4885CDK4 3/4885CDK1 14/4885 |
| US-20200339572-A1 | NOVEL SELECTIVE CDK4/6 INHIBITOR AND PREPARATION THEREOF | CDK4, CDK6, CCNI | CDK6 2/4885CDK4 1/4885CDK1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.